P
PathAI
AI-powered pathology platform optimizing diagnostic accuracy and research
About PathAI
PathAI is dedicated to improving patient outcomes through its AI-powered pathology platform. The company focuses on enhancing the accuracy of diagnoses and the efficacy of treatments for diseases such as cancer by leveraging advanced machine learning techniques. PathAI serves healthcare providers, research institutions, and pharmaceutical companies, operating primarily in the medical and healthcare markets. The business model revolves around providing AI-driven diagnostic tools and services, generating revenue through partnerships, licensing, and service fees. The company is headquartered in Fenway and boasts a diverse team committed to solving complex problems and making a significant impact. PathAI has also been recognized as one of BBJ's Best Places to Work.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2016
- Headquarters
- Boston, United States
- Employees
- 281
- Open positions
- 5
- Dealroom signal
- 84.1/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Oncology, Drug Development, Medical & Healthcare, Pathology, Medical Imaging
- Technology
- Artificial Intelligence, Big Data, Deep Tech, Machine Learning, Deep Learning
- Business model
- SaaS
- Client focus
- b2b
- Investment activity
- 1 company, latest Jul 2021
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | May 2026 | $750M | $750M | Roche | ↗ |
| DEBTDebt | Jan 2022 | $100M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for PathAI is 73K monthly website visits, down 22.3% over the last three months. PathAI's team grew 4.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
Fairhaven Capital Partners
Refactor Capital
8VC
Pillar VC
Series A6 investors entered at this stage
General Catalyst
KdT Ventures
General Atlantic
LabCorp
Bristol-Myers Squibb
Merck Global Health Innovation Fund
Series B and later6 investors entered at this stage
Kaiser Permanente
D1 Capital Partners
Polaris Partners
Biospring Partners
Tiger Global
Adage Ventures
Other known investors3 additional known investors
Beth Israel Deaconess Medical Center
Harvard University
Roche
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about PathAI on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See PathAI’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.